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his literature review presents current data on 
statins as anti-inflammatory agents in athero-
genesis. Molecular mechanisms responsible for 
the anti-inflammatory effects of statins and clinical data 
on the non-lipid-lowering, anti-inflammatory effect of 
statins on cardiovascular outcomes are described. Ana-
lyzed the results of several randomized clinical trials, in-
cluding GREACE, ALLIANCE, TNT, PLANET I, PLANET II, as 
well as other studies and meta-analyses. Since, cardiova-
scular events and renal dysfunction are associated with 
increased morbidity, lower quality of life and higher mor-
tality rates. The results of statin therapy in recent large 
randomized clinical trials are also discussed. Prospects for 
further studies to compare the clinical efficacy of statins 
in situations where there is a risk of kidney damage are 
discussed. The question of preliminary (load) administrati-
on of statins in patients with the acute coronary syndrome 
with ST-elevation remains relevant (STEMI).
Keywords: acute coronary syndrome, statins, chronic 
kidney disease.
sta revisión de la literatura presenta datos ac-
tuales sobre las estatinas como agentes anti-
inflamatorios en la aterogénesis. Se describen 
los mecanismos moleculares responsables de los efectos 
antiinflamatorios de las estatinas y los datos clínicos so-
bre el efecto antiinflamatorio no reductor de lípidos de 
las estatinas en los resultados cardiovasculares. Se anali-
zaron los resultados de varios ensayos clínicos aleatorios, 
incluidos GREACE, ALLIANCE, TNT, PLANET I, PLANET II, 
así como otros estudios y metanálisis. Desde entonces, 
los eventos cardiovasculares y la disfunción renal se aso-
cian con una mayor morbilidad, menor calidad de vida 
y mayores tasas de mortalidad. También se discuten los 
resultados del tratamiento con estatinas en los grandes 
ensayos clínicos aleatorizados recientes. Se discuten las 
perspectivas de estudios adicionales para comparar la efi-
cacia clínica de las estatinas en situaciones donde existe 
un riesgo de daño renal. La cuestión de la administración 
preliminar (de carga) de estatinas en pacientes con sín-
drome coronario agudo con elevación del ST sigue siendo 
relevante (STEMI).
Palabras clave: síndrome coronario agudo, estatinas, en-
fermedad renal crónica.
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urrently, cardiovascular diseases (CVDs) 
are the first cause of death in the Russian 
Federation and account for 56.8% of all 
deaths. The problem of adequate medical management 
of older patients is of great importance1. This is due to 
the existing objective patterns of pharmacodynamics and 
pharmacokinetics of drugs in the elderly and senile pa-
tients, the need to use special drug forms, making them 
more accessible to elderly patients, who suffer, as a rule, 
from pathology of the organ of vision, small joints of the 
hand with a decrease in its function, and cognitive disor-
ders2. An important aspect of the use of drugs in geriat-
rics is often a low level of patient adherence thereto, a 
low level of awareness of the specifics of geriatric therapy 
among doctors of the primary medical network3. All of 
the above can be fully attributed to such an important 
group of drugs like statins.
Main Part: There is an opinion that using statins for pri-
mary prevention is recommended for people at risk of 
CVDs due to atherosclerosis, when it is 7.5% or more. 
This means that most men over 60 and women over 70 
may have indications for taking statins. Moreover, the 
results of a recently published analysis indicate that only 
23.6% of adults, whose average age is 61.1±6.9 years, 
did not have formal indications for taking statins, which 
would be based on modern clinical guidelines or results 
of randomized clinical trials (RCT). Concerning the expan-
sion of indications for the use of statins, both more inten-
sive and less intensive statin regimens have come to the 
attention of doctors and researchers again. The HOPE-3 
study (Heart Outcomes Prevention Evaluation 3)4, which 
included patients without CVDs, who had an average risk 
of developing CVD complications, as well as the moder-
ate level of blood lipids and blood pressure, indicated that 
taking rosuvastatin 10 mg/day compared with placebo for 
an average of 5.6 years resulted in a decrease in concen-
tration of cholesterol (CH) of low-density lipoprotein (LDL) 
by 26.5% and in a statistically significant decrease in the 
first main composite mortality from CVD complications 
(CVDs), the rate of development of non-lethal myocardial 
infarction or non-fatal stroke by 24% (risk ratio 0.76 with 
a 95% confidence interval from 0.64 to 0.91; p = 0.002).
Acute coronary syndrome (ACS) is one of the main causes 
of mortality due to cardiovascular disease. It should be 
noted that cardiovascular events and renal dysfunction are 
associated with increased morbidity, reduced quality of life 
and higher mortality rates5,6. Several risk factors have been 
identified in renal failure against a background of cardio-
vascular events: dyslipidemia, hypertension, and diabetes7.
Along with the lipid-lowering action, numerous pleiotro-
pic (non-lipid) effects of statins have been established, 
including: the effect on oxidized lipoproteins; improved 
endothelial function; reduced cell adhesion; anti-inflam-
matory effect; inhibition of proliferation and migration 
of smooth muscle cells; stabilization of atherosclerotic 
plaque; decreased platelet aggregation; improvement of 
the fibrinolytic system; impact on other organs and sys-
tems (prevention of osteoporosis, bone fractures; reduc-
tion of cholesterol bile saturation, dissolution of cholester-
ol stones, a tendency to decrease in carcinogenicity, pre-
vention of Alzheimer’s disease and vascular dementia)8,9. 
Statins can have an anti-atherosclerotic effect regardless 
of their lipid-lowering action. Since metabolism of mev-
alonate creates a series of isoprenoids, vital for various 
cellular functions - from the synthesis of cholesterol (CH) 
to controlling cell growth and differentiation, inhibition 
of HMG-CoA reductase has favorable pleiotropic effects. 
Therefore, statins significantly reduce the incidence of dis-
eases of coronary arteries, play a role in both primary and 
secondary prevention, being the most effective lipid-low-
ering compounds that reduce mortality in patients with 
coronary disease. The analysis of direct clinical factors af-
fecting the incidence of renal diseases showed that plas-
ma lipid concentration is not of key importance. Statins 
have pleiotropic effects, and some of their actions may be 
mediated in other ways.
In recent years, synthetic statins (atorvastatin, rosuvas-
tatin) have attracted the attention of researchers. Based 
on the structure and origin of the two drugs, it seems 
impossible today to identify the most effective of them. 
In this regard, it is necessary to focus on how they differ 
from each other in their absorption and distribution in the 
body, as well as the effectiveness of their impact on the 
level of cholesterol (CH) and lipoproteins of various densi-
ties with a personalized approach in certain categories of 
patients. At the same time, statins, through a variety of 
mechanisms, can have a significant protective effect on 
the functional abilities of the kidneys10. We should note 
that synthetic statins differently affect renal function, as 
evidenced by the results of direct and indirect comparisons 
of atorvastatin and rosuvastatin. Significant renal protec-
tion property of atorvastatin is confirmed by the results of 
several RCTs, including GREACE, ALLIANCE, TNT, PLANET 
I, PLANET II, as well as other research and meta-analyses. 
GREACE (GREek Atorvastatin and Coronary heart disease 
Evaluation)11 showed that atorvastatin significantly in-
creased the creatinine clearance (CC) by 12% of baseline 
in patients with dyslipidemia with coronary artery disease 
(CAD) and initially normal kidney function, and reduced 
CC by 5.2% in patients not treated with statins. Thus, 
GREACE proved that atorvastatin has renal protective ef-
fects in patients with stable coronary artery disease (CAD) 
and showed that these effects are more pronounced in 
patients with initially reduced renal function, that they 
depend on the dose of the drug, and that atorvastatin 
increases CC more than other statins (simvastatin, pravas-
tatin, fluvastatin)12. The ALLIANCE study (Aggressive Lipid-
Lowering Initiation Abates New Cardiac Events) involved 
an assessment of the change in the level of the estimated 
glomerular filtration rate in patients receiving atorvastatin 
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during 4 years of follow-up compared with standard treat-
ment. Atorvastatin has been found to protect renal func-
tion and slow the progression of chronic kidney disease 
(CKD) and significantly delayed the development of the 
first cardiovascular complication compared with standard 
therapy12,13. A large-scale meta-analysis of 27 studies that 
included data on 39,704 patients found that statin ther-
apy causes a statistically significant slowdown in the rate 
of decrease in the estimated glomerular filtration rate. At 
the same time, the analysis by subgroups showed that 
the use of atorvastatin is associated with a significantly 
more pronounced positive effect on the renal function 
compared to other statins. A large double-blind RCT - 
TNT that included 10,001 patients with CAD and LDL CH 
<130 mg/dl14 compared the effects of low (10 mg/day) and 
high (80 mg/day) doses of atorvastatin on the change in 
the level of the estimated glomerular filtration rate. Thus, 
the TNT study showed that atorvastatin 80 mg/day has a 
significantly more pronounced renal protective and car-
dioprotective effects compared with atorvastatin 10 mg/
day, especially in patients with advanced CKD15. The idea 
of positive renal effects of atorvastatin was confirmed in 
studies assessing the effects on proteinuria. For example, 
the works by Bianchi S. et al. showed that patients with 
CKD, proteinuria, and hypercholesterolemia who received 
an angiotensin-converting enzyme inhibitor or angioten-
sin II receptor blocker for a year have a decrease in their 
level of proteinuria after a year in the atorvastatin group 
from 2.2 to 1.2 g/day, and from 2.0 to 1.8 g/day in the 
control group that did not receive atorvastatin. During the 
same time, there was a slight change in CC (from 51.0 to 
49.8 ml/min) in the atorvastatin group and a significant 
decrease (from 50.0 to 44.2 ml/min) in the control group16.
The renal protective effects of atorvastatin and rosuvas-
tatin were compared in two RCTs - PLANET I and PLANET 
II17, which included patients with initial moderate protein-
uria and hypercholesterolemia with diabetes mellitus. The 
drugs were compared in high dosages, so the target dose 
of atorvastatin was 80 mg/day and rosuvastatin 40 mg/
day; the observation period was 52 weeks. The results of 
the study showed that the studied drugs had a different 
effect on kidney function: atorvastatin in both studies sig-
nificantly reduced the severity of proteinuria (on average 
by 15% in PLANET I and more than 20% in PLANET II), 
while rosuvastatin did not affect it in PLANET I or its ef-
fect was not statistically significant in the PLANET II study. 
The effect of statins on the glomerular filtration rate (GFR) 
was also different: in the atorvastatin groups, the change 
was statistically insignificant, whereas rosuvastatin 40 
mg/day reduced GFR (statistically significant decrease in 
GFR in PLANET II among patients without diabetes mel-
litus). In addition to these effects, in PLANET I with the 
use of rosuvastatin, an increase in the frequency of kidney 
complications was noted against the background of good 
general tolerability of therapy (a 4-fold increase in the risk 
of developing acute renal failure and a 5-fold increase in 
the risk of doubling serum creatinine levels compared to 
80 mg/day atorvastatin therapy. Thus, the PLANET I and 
PLANET II RCTs showed that high doses of atorvastatin sig-
nificantly reduce the severity of proteinuria (decrease by 
20%) without adverse effects on the renal function, while 
rosuvastatin therapy leads to a significant reduction in re-
nal function without reducing the severity of proteinuria17. 
Assessment of the effect of rosuvastatin on renal function 
in other studies showed results that are largely compa-
rable with data from the PLANET I and II RCTs. Two stud-
ies - POLARIS and SOLAR, which compared atorvastatin 
and rosuvastatin in patients with hypercholesterolemia, 
showed that rosuvastatin increased the severity of pro-
teinuria to a greater extent than atorvastatin18,19. Also, 
in two placebo-controlled studies involving patients with 
chronic heart failure -GISSI-HF and CORONA, rosuvastatin 
therapy caused a 5-fold increase in the incidence of renal 
failure in the CORONA study20 and a numerically higher 
incidence of renal dysfunction, acute renal failure, and a 
2-fold increase in serum creatinine in GISSI-HF21. Finally, a 
post-registration analysis of the effects of rosuvastatin re-
vealed a higher risk of developing proteinuria, nephropa-
thy, renal failure, toxic liver damage, muscle toxicity, and 
rhabdomyolysis during treatment with rosuvastatin com-
pared to other statin drugs22.
Previously, clinical practice guidelines suggested using 
target values for LDL cholesterol, which require repeated 
measurements. An escalation of treatment with higher 
statin doses could be a result of unmet targets of LDL 
cholesterol. The KDIGO (Kidney Disease: Improving Global 
Outcomes) research group did not recommend this strat-
egy, as higher doses of statins have not been proven in 
terms of GFR safety. Since LDL levels do not necessarily 
indicate the need to increase statin doses, subsequent 
measurement of lipid levels is not recommended. 
Patients with ST-segment elevation myocardial infarction 
(STEMI) showed that a preliminary (loading) high dose 
of atorvastatin prevented contrast-induced nephropathy 
(CIN) and protect kidney function after emergency PCI20. 
To compare statins, a post-hoc analysis combined data 
from PLANET I with data from PLANET II. Although rosuv-
astatin in a high dose reduces plasma lipid concentrations 
to a greater extent than a high dose of atorvastatin, atorv-
astatin appears to have a higher renal protective effect for 
the studied CKD population23. Comparison of the effect 
of loading dose on the frequency of CIN between atorv-
astatin and rosuvastatin in patients with STEMI undergo-
ing PCI (atorvastatin 80 mg (n=98) or rosuvastatin 40 mg 
(n=94) before the procedure) showed that the incidence 
of CIN was 8.9% (n=17) in all groups. It was determined 
that only the amount of contrast agent administered is 
an independent predictor for CIN, while the ejection frac-
tion (EF) of the left ventricle showed marginal statistical 
significance. This study showed that atorvastatin and ro-
suvastatin had similar efficacy in the prevention of CIN in 
patients with STEMI undergoing PCI24. The prophylactic 
effect of rosuvastatin and atorvastatin on CIN in patients 
with CKD undergoing PCI (rosuvastatin 10 mg, and atorv-
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astatin 20 mg) was also prospectively compared. CIN was 
observed in 58 (5.4%) patients. In general, it was con-
cluded that rosuvastatin and atorvastatin have similar ef-
ficacy for the prevention of CIN in patients with CKD who 
underwent PCI. In general, the analysis of the conducted 
studies shows that atorvastatin may have the strongest re-
nal protective effects. But there are still a lot of questions 
in individual categories of patients with ACS, dependence 
on the duration, age of patients, EF, the left ventricle (LV) 
volume, and LV diastolic function.
Clinical studies with atorvastatin have found a significant 
reduction in cardiovascular events in patients with and 
without CAD. Studies show that a high dose of atorvas-
tatin will reduce LDL to about 70 mg/dL in many patients 
and improve heart outcomes. Available research data sug-
gest that a high dose of atorvastatin may stop and cause 
an atherosclerotic progression to regress. Studies of the 
effects of statins in patients with diabetes have shown 
that atorvastatin reduces the occurrence of acute, clini-
cally significant cases of CAD, coronary revascularization, 
and stroke. Atorvastatin is effective in reducing nonfatal 
myocardial infarction and fatal CAD in hypertensive pa-
tients with three or more additional risk factors. A high 
dose of atorvastatin is effective in elderly patients who 
have recently undergone STEMI and to slow down the 
cognitive decline in preliminary studies in Alzheimer’s pa-
tients. Limitations of this review include the lack of gen-
eralizability of atorvastatin research data for other statins, 
the lack of tests for initial brain results involving newer 
statins, and relatively short study durations (none exceed 5 
years) while atherosclerosis is usually a long-term illness. A 
convincing body of evidence suggests that atorvastatin re-
duces major cardiovascular events in both secondary and 
primary prevention of CAD. Besides, atorvastatin is safe 
and well-tolerated throughout the entire dose range25. It 
should be noted that several studies have shown the ad-
ditional effect of statins on slowing the progression of dia-
betic nephropathy. However, few reports directly compare 
the renal protective effects of active and normal statins. 
CKD has been proven to be associated with inflamma-
tion. The effect of atorvastatin on inflammatory biomark-
ers was evaluated in patients with CKD in a LORD study. 
In patients with elevated baseline IL-6/8/10 and/or pen-
taxin-3 (PTX3) plasma levels, a decrease in GFR during 
the study was significantly lower in patients who received 
atorvastatin compared with placebo, while those with no 
inflammatory biomarkers showed no differences. Patients 
receiving placebo with elevated levels of tumor necrosis 
factor-a (TNF-α) did not have a decrease in GFR, whereas 
patients receiving atorvastatin had a decrease in their GFR. 
Large-scale studies with statin therapy, particularly in pa-
tients with inflammation-related CKD, may be useful for 
studying26. Since dyslipidemia is an independent risk factor 
for CKD progression, then the - absorbing therapy may be 
potentially associated with inhibition of CKD progression. 
A clinical benefit assessment in patients with CKD with 
atorvastatin was developed to determine whether ator-
vastatin has a protective effect on kidney function in pa-
tients with dyslipidemia and CKD. This study differs from 
similar ones by an increase in statistical accuracy obtained 
from its much larger sample size and longitudinal value27. 
It has been suggested that the renal protective effects of 
statins may be the result of effects on endothelial cell func-
tion. nitrogen oxides (NO) mediates endothelial vasodila-
tion and also contributes to both natriuresis and diuresis 
by increasing renal blood flow and GFR28. NO also increas-
es renin secretion29. Statins have been shown to improve 
the activity of basal nitrogen oxides (NO) and nitrogen ox-
ide-dependent endothelial vasodilation in healthy volun-
teers and patients with heart disease30. There is currently 
no effective strategy to prevent impaired renal function, 
and therefore the renal protective effects of statins are 
of promising importance. Atorvastatin increases the avail-
ability of nitrogen oxides (NO), prevents the formation of 
oxygen free radicals and reduces the regulation of expres-
sion of cyclooxygenase 231. 
A significant trial of Justification for the Use of Statins 
in Prevention: an Intervention Trial Evaluating Rosuvas-
tatin (JUPITER) has found that suppression of low-grade 
inflammation with statins (rosuvastatin) improves clinical 
outcome in the subjects without CAD. We should also 
note a smaller number of adverse effects when using ro-
suvastatin 10 mg/day compared with the more intensive 
rosuvastatin regimen in Justification for the Use of Statins 
in Prevention: an Intervention Trial Evaluating Rosuvas-
tatin (JUPITER)32. Also, by modern clinical guidelines for 
the treatment of dyslipidemia, intensive statin regimens 
are considered impractical for people older than 75 years 
due to an increased risk of adverse effects33-38.
Summary: The anti-inflammatory effect of statins is well 
known and may have relevance to their renal protective 
effects. By inhibiting the formation of intracellular isopren-
oids, statins inhibit vascular and myocardial inflammation, 
modulate vascular and myocardial redox state favorably 
and improve the bioavailability of nitric oxide. Thus, cur-
rently available data suggest that the use of statins has a 
positive effect on the level of lipids in the blood of elderly 
people. Due to the increase in the share of elderly and 
senile people in Russia, as well as the high mortality from 
CVD complications, many elderly people in our country 
may have strong clinical reasons for choosing statins as a 
basic lipid-lowering therapy.
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